Marian Emanuela, Baraldo Simonetta, Visentin Annalisa, Papi Alberto, Saetta Marina, Fabbri Leonardo M, Maestrelli Piero
Dipartimento di Medicina Ambientale e Sanità Pubblica, Università degli Studi di Padova, via Giustiniani, 2, 35128 Padova, Italy.
Chest. 2006 Jun;129(6):1523-30. doi: 10.1378/chest.129.6.1523.
We investigated the role of two leukotriene B4 (LTB4) receptors, BLT1 and peroxisome proliferator-activated receptor (PPAR)-alpha, in conferring the susceptibility to develop COPD in smokers. Proinflammatory LTB4 activities are mediated by BLT1, while the inactivation of LTB4 is promoted by PPARalpha.
BLT1 and PPARalpha proteins were quantified by immunohistochemistry in specimens obtained during lung surgery from 19 smokers with or without COPD and from 7 nonsmoking subjects.
We have shown that the percentages of PPARalpha-positive alveolar macrophages and PPARalpha-positive cells in the alveolar wall were increased in COPD patients compared with control subjects. Moreover, the patients with COPD exhibited a significant increase of BLT1-positive alveolar macrophages compared with nonsmokers and an increased number of BLT1-positive cells in the alveolar walls compared with non-COPD smokers. In contrast, BLT1 and PPARalpha immunoreactivity did not differ significantly between nonsmokers and non-COPD smokers. Most of BLT1-positive cells in the alveolar walls were neutrophils and CD8 cells. While the number of neutrophils infiltrating the lung parenchyma was similar among the three groups, the number of CD8 T cells was increased in COPD patients, but there was no evidence that BLT1 was up-regulated specifically on these cells in COPD patients.
The results demonstrated that BLT1 and PPARalpha are detectable in alveolar macrophages and CD8 T cells in human lung tissue, and suggest that the dual LTB4 receptor system is up-regulated in the peripheral lungs of smokers who are susceptible to the development of COPD. This system might represent a novel target for therapeutic intervention in COPD patients.
我们研究了两种白三烯B4(LTB4)受体,即BLT1和过氧化物酶体增殖物激活受体(PPAR)-α,在吸烟者患慢性阻塞性肺疾病(COPD)易感性中的作用。促炎LTB4活性由BLT1介导,而LTB4的失活由PPARα促进。
通过免疫组织化学对19例有或无COPD的吸烟者及7例非吸烟者在肺手术中获取的标本进行BLT1和PPARα蛋白定量。
我们发现,与对照组相比,COPD患者中PPARα阳性肺泡巨噬细胞和肺泡壁中PPARα阳性细胞的百分比增加。此外,与非吸烟者相比,COPD患者中BLT1阳性肺泡巨噬细胞显著增加,与非COPD吸烟者相比,肺泡壁中BLT1阳性细胞数量增加。相比之下,非吸烟者和非COPD吸烟者之间BLT1和PPARα免疫反应性无显著差异。肺泡壁中大多数BLT1阳性细胞为中性粒细胞和CD8细胞。虽然三组中浸润肺实质的中性粒细胞数量相似,但COPD患者中CD8 T细胞数量增加,但没有证据表明COPD患者这些细胞上的BLT1特异性上调。
结果表明,在人肺组织的肺泡巨噬细胞和CD8 T细胞中可检测到BLT1和PPARα,提示在易患COPD的吸烟者外周肺中双LTB4受体系统上调。该系统可能是COPD患者治疗干预的新靶点。